Categories: News

Soleno Therapeutics Announces Presentations at ENDO 2022

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.

Details of the presentations are as follows:

2022 Endocrine Society Meeting (ENDO)

Title: Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
Format: Oral Presentation
Presenter: Dr. Eric Felner on behalf of the DESTINY PWS Investigators and Soleno Therapeutics
Date: Sunday, June 12, 2022
Time: 11 AM to 12:30 PM Eastern Time

Title: Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
Format: Poster
Presenter: Dr. Michael Woloschak on behalf of the DESTINY PWS Investigators and Soleno Therapeutics
Date: Sunday, June 12, 2022
Time: 1:00 PM ET

The copy of the presentation materials will be available in the Investors section on the Company’s website at www.soleno.life after presentation at the meeting.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

Staff

Recent Posts

NuGen Medical Devices Inc. Provides Update on Health Canada License

Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

5 hours ago

Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026

Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field AblationCARDIFF-BY-THE-SEA, Calif., Feb. 5,…

5 hours ago

LEADOPTIK Announces First-in-Human Use of FDA-Cleared LIA™ System

SAN JOSE, Calif., Feb. 5, 2026 /PRNewswire/ -- LEADOPTIK, Inc., a medical technology company focused…

5 hours ago

Dräger PSS® AirBoss SCBA Now Available for Purchase in North America

Now Available for Purchase, AirBoss Delivers an NFPA 1970:2025 SCBA Built for the Way American…

11 hours ago

Greenway Health® Named Most Improved Physician Practice Solution 2026 by KLAS Research

KLAS recognition highlights Greenway's momentum in modernizing physician practice technologyTAMPA, Fla., Feb. 5, 2026 /PRNewswire/…

11 hours ago

Huckleberry Launches Berry: Specialized AI that Brings Family Context Front and Center

While AI booms, Berry delivers quiet confidence to parents by pairing each child's unique logged…

11 hours ago